Intellia Therapeutics Inc NTLA

NAS: NTLA | ISIN: US45826J1051   30/04/2025
8,870 USD (+8,17%)
(+8,17%)   30/04/2025

23 april 2025 · Lawsuit for Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced by the Shareholders Foundation · Persbericht

11 april 2025 · Intellia Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - NTLA · Persbericht

10 april 2025 · SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics · Persbericht

8 april 2025 · Class Action Filed Against Intellia Therapeutics, Inc. (NTLA) Seeking Recovery for Investors - Contact Levi & Korsinsky · Persbericht

3 april 2025 · NTLA Investors Have Opportunity to Lead Intellia Therapeutics Securities Fraud Lawsuit with Faruqi & Faruqi, LLP · Persbericht

1 april 2025 · Shareholders that lost money on Intellia Therapeutics, Inc.(NTLA) should contact Levi & Korsinsky about pending Class Action - NTLA · Persbericht

28 maart 2025 · Levi & Korsinsky Notifies Intellia Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - NTLA · Persbericht

21 maart 2025 · Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Intellia Therapeutics, Inc. Lawsuit - NTLA · Persbericht

18 maart 2025 · Shareholders that lost money on Intellia Therapeutics, Inc.(NTLA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More · Persbericht

12 maart 2025 · Shareholders that lost money on Intellia Therapeutics, Inc.(NTLA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More · Persbericht

7 maart 2025 · Levi & Korsinsky Notifies Shareholders of Intellia Therapeutics, Inc.(NTLA) of a Class Action Lawsuit and an Upcoming Deadline · Persbericht

7 maart 2025 · Levi & Korsinsky Notifies Shareholders of Intellia Therapeutics, Inc.(NTLA) of a Class Action Lawsuit and an Upcoming Deadline · Persbericht

4 maart 2025 · Levi & Korsinsky Reminds Intellia Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025 - NTLA · Persbericht

18 oktober 2023 · Thinking about trading options or stock in Palantir Technologies, Macy's, Intellia Therapeutics, Shopify, or Brinker International? · Persbericht

16 september 2022 · Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis · Persbericht

24 juni 2022 · Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single Dose · Persbericht

28 februari 2022 · Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein · Persbericht

26 juni 2021 · Intellia and Regeneron Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single Infusion of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis · Persbericht

10 maart 2021 · Intellia Therapeutics Presents Preclinical Proof of Concept for CRISPR-based In Vivo Editing of Bone Marrow at Keystone eSymposium · Persbericht

25 februari 2021 · Intellia Therapeutics Announces Fourth Quarter and Full-Year 2020 Financial Results · Persbericht

Mijn selecties